Author: Jeanene Swanson

News, Research

Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD

Jeanene Swanson

On Nov. 19, Santhera Pharmaceuticals announced publication of long-term data from its SYROS study showing a reduction of decline in lung function in people with Duchenne muscular dystrophy (DMD) who were treated with idebenone, the company’s experimental therapy for respiratory symptoms associated with DMD. The data from the retrospective study was published in the journal Neuromuscular . . .

Read More
News, Research

FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping

Jeanene Swanson

On Dec. 12, the US Food and Drug Administration (FDA) granted accelerated approval to golodirsen (Vyondys 53) for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 53. It is the second exon-skipping, disease-modifying drug to treat DMD, the most common childhood form of muscular dystrophy. The drug is administered by intravenous . . .

Read More
News, Research

Kadimastem Announces Positive Interim Results from Phase 1/2a Study of AstroRx in ALS

Jeanene Swanson

Israel-based Kadimastem Ltd. announced positive interim results from the first cohort of its phase 1/2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of AstroRx in patients with amyotrophic lateral sclerosis (ALS). Results presented at the 7th International Stem Cell Meeting of the Israel Stem Cell Society held recently in Tel Aviv, Israel, showed that patients . . .

Read More
News, Research

FDA Accepts Roche Genentech’s NDA for Risdiplam for the Treatment of SMA

Jeanene Swanson

On Nov. 25, Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) seeking approval under Priority Review for risdiplam, an investigational therapy for the treatment of spinal muscular atrophy (SMA). Priority Review status requires the FDA to review the application and decide on whether . . .

Read More
News, Research

Zogenix Announces Positive Results from Pivotal Study of Investigational Treatment MT1621 for TK2 Deficiency

Jeanene Swanson

At the 24th Annual Congress of the World Muscle Society (WMS) held in October 2019 in Copenhagen, Denmark, Zogenix presented positive results from its pivotal phase 2 retrospective clinical trial (RETRO) testing the safety and efficacy of pyrimidine nucleoside substrate enhancement therapy (SET) MT1621 for treating thymidine kinase 2 (TK2) deficiency. The experimental therapy was developed . . .

Read More
News, Research

Roche Genentech Announces Positive Results from Pivotal Study of Risdiplam in SMA Types 2 and 3

Jeanene Swanson

On Nov. 10, Genentech, a member of the Roche Group, announced positive results from the second part of its pivotal phase 2/3 SUNFISH clinical trial assessing risdiplam in patients with spinal muscular atrophy (SMA) types 2 or 3. The study met its primary endpoint, which was change from baseline in the Motor Function Measure 32 (MFM-32) . . .

Read More
News, Research

MDA Care Centers Combine Expert Care with Research, Clinical Trials, and Advanced Technology

Jeanene Swanson

At more than 150 of the leading healthcare institutions across the US, MDA Care Centers offer top clinical care to individuals living with muscular dystrophy, ALS, and other neuromuscular diseases. Providing access to this expert multidisciplinary care, however, is just one way that Care Centers serve the neuromuscular community. MDA Care Centers are conducting clinical . . .

Read More
News, Research

World Muscle Society Roundup: Clinical Trial Results of Treatments in Development for DMD, XLMTM, SMA, and Pompe Disease

Jeanene Swanson

Several biotech and pharma companies presented interim results at the 24th Annual Congress of the World Muscle Society (WMS) held earlier this month in Copenhagen, Denmark. This roundup covers a few of these updates. Catabasis Pharmaceuticals presented positive results from its phase 1/2 MoveDMD trial and open-label extension with edasalonexent in boys with Duchenne muscular . . .

Read More
News, Research

Reata Pharmaceuticals Announces Positive Results from Pivotal Study of Omaveloxolone in FA

Jeanene Swanson

Texas-based Reata Pharmaceuticals announced positive results of its pivotal phase 2 clinical trial (MOXIe) of omaveloxolone in patients with Friedreich’s ataxia (FA). Patients treated with omaveloxolone showed a statistically significant improvement in the modified Friedreich’s Ataxia Rating Scale mFARS (a scale used to measure neurological function) after 48 weeks of treatment compared to placebo, and . . .

Read More
1234...Last